Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Florence
Clinical trial register · Italy

Clinical Trials in Florence, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Italy and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6778 matching records held by the registry are in this view. Synced 08 Oct 2026, 03:19 UTC
6778
Studies in scope
all four open statuses
4069
Recruiting now
open to new participants
1018
Lead sponsors
across recruiting studies
Top sites
Milan 73 Roma 52 Rozzano 26 Florence 24 Ancona 24
Narrow the registerReset
Recruitment status
Phase
Site location
Milan73 Roma52 Rozzano26 Florence24 Ancona24
All 66 locations
Target enrolment
to

Trials with a site in Florence

24 of 6778 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Italy
Start
Recruiting
Novartis Pharmaceuticals
Phase 2
60
Florence, Roma, Trieste, Vicenza
2026-06-26
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Novartis Pharmaceuticals
Phase 3
460
Meldola, Florence, Padova, Roma, Verona, Novara
2026-05-27
Recruiting
Novartis Pharmaceuticals
Phase 3
5,700
Ancona, Bergamo, Bologna, Brescia, Cona, Florence, Pozzilli, Milan
2026-05-11
Recruiting
Novartis Pharmaceuticals
Phase 2
272
Florence, Milan, Roma
2026-03-09
Recruiting
Novartis Pharmaceuticals
Observational
50
Alessandria, Avellino, Brescia, Florence, Genova, Milan, Palermo, Roma
2026-01-13
Recruiting
Novartis Pharmaceuticals
Observational
250
Ancona, Bari, Brescia, Cona, Florence, Genova, Lecce, Messina
2025-12-17
Recruiting
Novartis Pharmaceuticals
Phase 2
30
Florence, Genova, Roma
2025-11-03
Active, closed
Novartis Pharmaceuticals
Phase 3
588
Ancona, Brescia, Catania, Cona, Florence, Rozzano, Modena, Pisa
2025-01-31
Recruiting
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
NCT06401356Hematologic Malignancy, Solid Tumor, Advanced Malignancies
Novartis Pharmaceuticals
Phase 3
50
Florence, Varese, Novara
2024-08-13
Active, closed
Novartis Pharmaceuticals
Phase 3
146
Bologna, Florence, Genova, Milan, Palermo, Roma, Orbassano
2024-07-31
Recruiting
Novartis Pharmaceuticals
Phase 3
200
Brescia, Catania, Florence, Pavia, Roma, Naples
2023-05-11
Active, closed
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383Primary Prevention of Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals
Phase 3
14,012
Ancona, Brescia, Caserta, Chieti, Catanzaro, Florence, Chiavari, Genova
2023-03-09
Active, closed
Novartis Pharmaceuticals
Observational
242
Alessandria, Ancona, Bari, Bologna, Como, Cosenza, Catania, Florence
2023-03-02
Active, closed
Novartis Pharmaceuticals
Phase 2
33
Brescia, Florence, Genova, Milan, Roma
2023-02-28
Active, closed
Novartis Pharmaceuticals
Phase 3
226
Bologna, Florence, Roma, Trieste, Vicenza
2023-02-03
Active, closed
Novartis Pharmaceuticals
Phase 3
210
Bari, Bergamo, Bologna, Florence, Genova, Milan, Rozzano, Palermo
2021-12-17
Active, closed
Novartis Pharmaceuticals
Phase 3
17,004
Bologna, Brescia, Cona, Florence, Grosseto, Pozzilli, Milan, Rozzano
2021-11-23
Active, closed
Novartis Pharmaceuticals
Phase 3
208
Ascoli Piceno, Avellino, Florence, Milan, Roma, Torino, Bassano del Grappa
2021-07-27
Active, closed
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
NCT04603495Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Novartis Pharmaceuticals
Phase 3
430
Bergamo, Bologna, Brescia, Ferrara, Florence, Meldola, Milan, Monza
2021-04-09
Recruiting
Secukinumab Open Label Roll-over Extension Protocol
NCT04638647Autoimmunity, Inflammation
Novartis Pharmaceuticals
Phase 4
1,000
Florence, Reggio Emilia
2020-12-22
Active, closed
Pediatric Long-Term Follow-up and Rollover Study
NCT03975829Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood
Novartis Pharmaceuticals
Phase 4
163
Florence, Genova, Milan, Roma, Torino
2019-11-04
Active, closed
CINC424A2X01B Rollover Protocol
NCT02386800Primary Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease, Acute Myeloid Leukemia
Novartis Pharmaceuticals
Phase 4
279
Ancona, Bari, Bologna, Brescia, San Giovanni Rotondo, Florence, Milan, Rozzano
2015-03-05
Rows per page Showing 1–24 of 24
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Italian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 8 October 2026. https://priyalifescience.com/clinical-trials-italy/city/florence

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Italy and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,778 studies in total at the last sync on 08 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 24 of those studies with a site in Florence that also match the filters currently applied.

How many clinical trials are recruiting in Florence?

10 of the 24 studies on this page are recruiting new participants as of the 08 Oct 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 14 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Florence), 24 studies
PhaseStudiesRecruitingShare
Phase 314458.3%
Phase 24316.7%
Observational3212.5%
Phase 43112.5%

Most active sponsors

Lead sponsors with the most studies (Florence)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals2410
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.